| Secondary automated electrophysiology assay of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1 - BioAssay Summary BioAssay Type: Automated Electrophysiology, Patch Clamp, Single Concentration Activity in Multiplicates Observed ..more |
_ | Related BioAssays Related BioAssays |
||||||||||||||||||||||||||||||||||||||||||||||
Target
BioActive Compounds: 227 Depositor Specified Assays
Description: Data Source: Johns Hopkins Ion Channel Center (JHICC_Kir2.1_inhibitors_IWS) BioAssay Type: Automated Electrophysiology, Patch Clamp, Single Concentration Activity in Multiplicates Observed Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC) Center Affiliation: Johns Hopkins University, School of Medicine Screening Center PI: Min Li, Ph.D. Assay Provider: Elena Makhina Ph.D., University of Pittsburgh Network: Molecular Libraries Probe Production Centers Network (MLPCN) Grant Proposal Number: 1 R03 DA026212-01 Grant Proposal PI: Elena Makhina Ph.D., University of Pittsburgh Assay Implementation: Haibo Yu Ph.D., Hao-ran Wang Ph.D., Owen McManus Ph.D., and Meng Wu Ph.D. Name: Secondary automated electrophysiology assay of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1 Description: See the related assay (PubChem AID: 1672). Protocol Assay overview: The purpose of this assay is to test the compounds generated from the primary screen and subsequent validation and secondary screens for Kir2.1 (potassium inwardly-rectifying channel J2, KCNJ2) (Pubchem SAID 1843) using automated population patch clamp electrophysiology system IonWorks (Molecular Devices). Protocol for automated electrophysiology assay for Kir2.1: 1. Cell culture: Cells are routinely cultured in DMEM/F12 medium, supplemented with 10% Fetal Bovine Serum (FBS), 50 IU/ml penicillin, 50ug/ml streptomycin, and 500ug/ml G418. 2. Prepare 3X compound plates: test compounds are prepared using external buffer (140 mM K-gluconate, 1.8 mM CaCl2,1 mM MgCl2, 10 mM HEPES, 10 mM Glucose, pH 7.4); controls are external buffer (both with DMSO concentrations matched to that of test compounds) 3. Cell preparation: Cells are dislodged using 0.125 % Trypsin/EDTA and resuspended at 2X10E6 /mL in external buffer. 4. Patchplate hole test on Ionworks: External buffer is added to each well of a 384-well PPC plate, 3.5 uL/well, and hole resistance of each well is measured. 5. Cell plating on Ionworks: Cells are dispensed to the 384-well PPC plate on Ionworks, 3.5 uL/well. 6. Membrane permeablization: Cells are exposed to 0.1mg/mL amphotericin B in internal buffer (40 mM KCl, 100 mM K-gluconate, 1 mM MgCl2, 5mM HEPES,2 mM CaCl2 pH 7.2). 7. Currents are measured using the following voltage protocol: Hold cells at +10 mV, depolarize to -100 mV for 800 ms, back to +10 mV for 600 ms and run a ramp from -100 mV to +100 mV in 800 ms before back to +10 mV. 8. Dispense 3.5 ul /well of compounds to each well on Ionworks and incubate for 4 minutes. 9. Measure currents using the same protocol described in 7. 10. Calculate Inhibition (%) = (Iprecompound -Ipostcompound)/Iprecompound*100% 11. Calculate the average and standard deviation for negative control in each plate 12. Calculate the percentage with the following formula: Percentage = Inhibition (%) - (Avg-3*SD) Where: Percentage: percentage change of compound over those of negative controls and 3 times of its standard deviation. Avg: average of potentiation (%) of those of negative controls. SD: standard deviation of potentiation (%) of those of negative controls. 13. Outcome assignment: If the test compound causes Percentage of the Kir2.1 current at -100 mV in concentration tested to be greated than 0, the compound is considered to be active. Otherwise, the compound is designated as inactive. 14. Score assignment: An active test compound is assigned between 5 and 100 by Int (([Percentage]+4.54)/88.2)*0.95*100. An inactive test compound is assigned the score of 0. Result Definitions
** Test Concentration. Additional Information Grant Number: 1 R03 DA026212-01 Data Table (Concise) Classification
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||